+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastrointestinal Agents Market by Product Type (Antacids, Anti Diarrheals, Anti Emetics), Route Of Administration (Intramuscular, Intravenous, Oral), Distribution Channel - Global Forecast 2025-2030- Product Image
Gastrointestinal Agents Market by Product Type (Antacids, Anti Diarrheals, Anti Emetics), Route Of Administration (Intramuscular, Intravenous, Oral), Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Gastrointestinal Agents Market by Product Type (Antacids, Anti Diarrheals, Anti Emetics), Route Of Administration (Intramuscular, Intravenous, Oral), Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977939
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastrointestinal Agents Market grew from USD 60.06 billion in 2024 to USD 63.12 billion in 2025. It is expected to continue growing at a CAGR of 5.00%, reaching USD 80.51 billion by 2030.

Introducing the Evolving Dynamics of Gastrointestinal Agents and Their Strategic Importance in Addressing Digestive Health Challenges Globally

The gastrointestinal agents market encompasses a broad spectrum of therapies designed to alleviate, treat, and prevent conditions affecting the digestive tract. This landscape has become increasingly complex due to evolving patient needs, regulatory frameworks, and rapid advancements in drug formulations. Rising incidences of acid reflux, irritable bowel syndrome, and other gastrointestinal disorders have triggered heightened demand for effective interventions. Moreover, shifting demographics and a growing focus on preventive care have underscored the strategic importance of innovation and access.

Against this backdrop this executive summary provides a concise yet thorough examination of the critical factors shaping the gastrointestinal agents market. It is intended to equip pharmaceutical manufacturers distributors and healthcare decision makers with actionable insights into transformative trends tariff impacts segmentation nuances regional dynamics and competitive strategies. By synthesizing the latest developments and data you will gain a clear understanding of how to navigate current challenges and seize emerging opportunities in this vital therapeutic area

Exploring the Convergence of Precision Medicine Microbiome Innovations and Digital Health in Shaping the Future of Digestive Treatment Modalities

Over the past decade the gastrointestinal agents market has undergone profound transformation driven by technological advancements and shifting treatment paradigms. The advent of precision medicine has ushered in targeted therapies that address specific receptors and pathways associated with digestive disorders. Concurrently the proliferation of probiotic and prebiotic research has reshaped our understanding of gut microbiome modulation offering novel prevention and treatment strategies beyond traditional pharmacology.

In parallel digital health platforms and telemedicine services have altered patient engagement and treatment adherence patterns. Real time symptom tracking and personalized dosing regimens enabled by wearable devices and mobile applications have increased the demand for flexible oral formulations and patient centric drug delivery systems. Regulatory bodies have responded by streamlining approval processes for breakthrough therapies while enhancing post market surveillance to ensure safety. As a result the market is poised for further expansion guided by an interplay of science technology and patient empowerment

Analyzing the Multifaceted Effects of 2025 Tariff Revisions on Supply Chain Resilience and Cost Optimization Strategies in Gastrointestinal Therapies

The implementation of new United States tariff policies in 2025 has introduced a layer of complexity to the global supply chain for gastrointestinal agents. Increased duties on active pharmaceutical ingredients and excipients originating from select markets have led manufacturers to reassess sourcing strategies and manufacturing footprints. This shift has prompted a wave of cost reallocation as companies balance the imperative to maintain competitive pricing with the need to uphold stringent quality standards.

Consequently pharmaceutical firms have embarked on regional diversification by establishing or expanding production facilities closer to end markets to mitigate tariff exposure. Partnerships with domestic suppliers have been fast tracked while long term agreements with international vendors are being reevaluated. These adaptations have resulted in a gradual realignment of logistics networks and inventory management practices designed to optimize lead times and reduce total landed costs. Ultimately the cumulative tariff impact underscores the importance of supply chain resilience and strategic localization in sustaining market viability

Delving into Product Type Administration Modes and Distribution Channels to Uncover Tailored Strategies for Serving Diverse Gastrointestinal Therapy Segments

Insight into market segmentation reveals distinct dynamics across product types routes of administration and distribution channels. Within product type antacids continue to benefit from broad accessibility with subcategories such as calcium carbonate and magnesium hydroxide demonstrating stable demand due to their established safety profiles. Low prevalence yet high efficacy treatments like proton pump inhibitors have captured a premium positioning driven by esomeprazole and rabeprazole innovations. Probiotics underscore the rising emphasis on microbiome health with bifidobacterium and lactobacillus strains gaining traction among preventive care advocates.

Considering route of administration oral formulations dominated by tablets and capsules account for the majority of usage reflecting patient preference for convenience while infusion and bolus injections meet acute care requirements in hospital settings. Creams gels and suppositories provide targeted relief for local gastrointestinal symptoms in an ambulatory context. From a distribution perspective retail pharmacies remain the primary access point for prescription and over the counter gastrointestinal therapies complemented by the growing convenience of online pharmacy channels. Hospital pharmacies continue to facilitate intravenous and specialized formulations providing a holistic network that underpins product availability and patient adherence

Unpacking Diverse Growth Drivers and Healthcare Dynamics Across the Americas Europe Middle East Africa and Asia Pacific in Gastrointestinal Care

Regional analysis highlights unique growth drivers and challenges across the Americas Europe Middle East Africa and Asia Pacific. In the Americas population aging and rising healthcare expenditure have underpinned demand for both prescription and over the counter solutions particularly in North America where advanced reimbursement frameworks support innovative therapies. Latin America is characterized by expanding access initiatives and an increasing focus on chronic disease management which creates room for growth in preventive formulations.

In Europe Middle East and Africa regulatory harmonization efforts and pan regional health initiatives have accelerated market entry for novel agents. Growing private sector investment in the Gulf Cooperation Council region complements aging European populations with tailored service models. Meanwhile Asia Pacific boasts high growth potential fueled by improving healthcare infrastructure in key markets such as China India and Southeast Asia where shifting dietary patterns and urban lifestyles drive incidence of gastrointestinal disorders. Collaborative manufacturing partnerships and localized clinical research endeavors further reinforce regional momentum

Identifying Strategic Collaborations Pipeline Innovations and Portfolio Expansions Driving Competitive Advantage in Gastrointestinal Therapeutics

Leading pharmaceutical and biotech companies have distinguished themselves through a combination of innovative pipelines strategic collaborations and focused geographic expansions. Organizations with vertically integrated supply chains have been able to streamline development cycles from molecule identification through to commercial scale production. Recent alliances between large market incumbents and specialty science firms underscore a shared commitment to next generation receptor antagonists and microbiome therapies.

Meanwhile nimble midsize players have carved out niche positions by leveraging agility in clinical trial execution and flexible manufacturing frameworks. These companies are particularly active in advancing novel formulations of established molecule classes enabling incremental improvements in efficacy and patient experience. Larger global entities continue to reinforce their footprint through acquisitions that bring complementary products and proprietary technologies into established gastroenterology portfolios. Overall the competitive landscape reflects a balance of scale and specialization with continued emphasis on pipeline diversification and front line therapy enhancements

Optimizing Supply Chain Resilience Patient Centric Innovations and Regional Strategies to Drive Sustainable Growth in Gastrointestinal Markets

Stakeholders should prioritize supply chain agility by establishing dual sourcing arrangements and exploring nearshore manufacturing partnerships to reduce tariff exposure and lead time risks. Embracing patient centric formulation design can enhance adherence and support premium pricing through differentiated delivery systems that address specific symptom profiles. Integrating real time digital health tools with traditional care pathways offers a compelling opportunity to capture value from improved patient engagement and outcomes monitoring.

Furthermore decision makers are advised to deepen regional expertise by aligning portfolios with local disease prevalence patterns and reimbursement mechanisms. Strategic licensing and targeted acquisitions in emerging markets can expedite market entry and consolidate position in high growth territories. Finally fostering cross functional alliances that bridge clinical research regulatory affairs and commercial teams will accelerate time to market for breakthrough therapies and ensure cohesive stakeholder alignment throughout the product lifecycle

Detailing a Rigorous Mixed Method Research Framework Incorporating Primary Interviews Secondary Sources and Data Triangulation for Gastrointestinal Insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure comprehensive coverage and validated insights. Primary research involved executive interviews with senior leaders across pharmaceutical companies contract manufacturing organizations and distribution stakeholders to capture firsthand perspectives on emerging trends and strategic priorities. Secondary research encompassed an extensive review of peer reviewed journals regulatory documents and proprietary data sources focused on gastrointestinal pharmacology and market access frameworks.

Data triangulation techniques were applied to reconcile information from multiple vantage points reinforcing the accuracy of key findings. Detailed segmentation analyses were conducted using standardized classification criteria for product type route of administration and distribution channel mapping. Regional assessments incorporated demographic economic and healthcare system variables to contextualize growth trajectories. The result is a rigorously vetted body of knowledge designed to empower stakeholders with actionable intelligence

Synthesizing Major Trends Segmentation Dynamics Competitive Drivers and Strategic Imperatives That Will Shape the Gastrointestinal Agents Arena

This executive summary has illuminated the critical forces reshaping the gastrointestinal agents market from technological breakthroughs in precision medicine to the implications of new tariff regimes. Segmentation insights demonstrate the importance of nuanced strategies across product types routes of administration and distribution channels while regional analysis underscores the distinct dynamics across the Americas Europe Middle East Africa and Asia Pacific. Competitive assessments reveal that success hinges on a delicate balance of scale specialization and strategic partnerships.

Looking ahead the ability to integrate patient centric digital health solutions and optimize supply chain resilience will distinguish leaders in this evolving landscape. By leveraging data driven decision making and cultivating a culture of cross functional collaboration stakeholders can position themselves to capitalize on emerging opportunities and navigate regulatory complexities with confidence. The insights presented here lay the groundwork for informed strategic planning and sustained growth in the gastrointestinal therapy sector

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Antacids
      • Aluminum Hydroxide
      • Calcium Carbonate
      • Combination Formulations
      • Magnesium Hydroxide
      • Sodium Bicarbonate
    • Anti Diarrheals
      • Adsorbents
        • Bismuth Subsalicylate
        • Kaolin Pectin
      • Opioid Derivatives
        • Diphenoxylate Atropine
        • Loperamide
    • Anti Emetics
      • Dopamine Antagonists
        • Metoclopramide
        • Prochlorperazine
      • NK1 Receptor Antagonists
        • Aprepitant
        • Fosaprepitant
      • Serotonin Receptor Antagonists
        • Granisetron
        • Ondansetron
        • Palonosetron
    • H2 Receptor Antagonists
      • Cimetidine
      • Famotidine
      • Nizatidine
      • Ranitidine
    • Laxatives
      • Bulk Forming
        • Methylcellulose
        • Polycarbophil
        • Psyllium
      • Lubricant
      • Osmotic
        • Lactulose
        • Polyethylene Glycol
        • Sorbitol
      • Stimulant
      • Stool Softeners
    • Probiotics & Prebiotics
      • Prebiotics
        • Fructooligosaccharides
        • Inulin
      • Probiotics
        • Bifidobacterium
        • Lactobacillus
        • Saccharomyces Boulardii
    • Proton Pump Inhibitors
      • Esomeprazole
      • Lansoprazole
      • Omeprazole
      • Pantoprazole
      • Rabeprazole
  • Route Of Administration
    • Intramuscular
    • Intravenous
      • Bolus Injection
      • Infusion
    • Oral
      • Capsule
      • Liquid Syrup
      • Powder
      • Tablet
    • Topical
      • Creams
      • Gels
      • Suppositories
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Novartis AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Bayer AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of microbiome modulation therapies to treat functional gastrointestinal disorders
5.2. Rising adoption of peptide-based therapeutics for advanced inflammatory bowel disease management
5.3. Integration of digital health solutions and remote monitoring in chronic gastrointestinal disease treatment
5.4. Growing demand for noninvasive diagnostic biomarkers in early detection of gastrointestinal cancers
5.5. Increasing pipeline focus on targeted therapies for celiac disease and gluten sensitivity
5.6. Development of next generation proton pump inhibitors with improved safety profiles
5.7. Surge in clinical research on gut-brain axis modulation for IBS and functional disorders
5.8. Innovations in oral small molecule therapeutics for ulcerative colitis and Crohn’s disease
5.9. Emergence of biosimilar agents competing with originator biologics in GI inflammatory disease
5.10. Adoption of personalized medicine approaches driven by genomic profiling in gastrointestinal care
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gastrointestinal Agents Market, by Product Type
8.1. Introduction
8.2. Antacids
8.2.1. Aluminum Hydroxide
8.2.2. Calcium Carbonate
8.2.3. Combination Formulations
8.2.4. Magnesium Hydroxide
8.2.5. Sodium Bicarbonate
8.3. Anti Diarrheals
8.3.1. Adsorbents
8.3.1.1. Bismuth Subsalicylate
8.3.1.2. Kaolin Pectin
8.3.2. Opioid Derivatives
8.3.2.1. Diphenoxylate Atropine
8.3.2.2. Loperamide
8.4. Anti Emetics
8.4.1. Dopamine Antagonists
8.4.1.1. Metoclopramide
8.4.1.2. Prochlorperazine
8.4.2. NK1 Receptor Antagonists
8.4.2.1. Aprepitant
8.4.2.2. Fosaprepitant
8.4.3. Serotonin Receptor Antagonists
8.4.3.1. Granisetron
8.4.3.2. Ondansetron
8.4.3.3. Palonosetron
8.5. H2 Receptor Antagonists
8.5.1. Cimetidine
8.5.2. Famotidine
8.5.3. Nizatidine
8.5.4. Ranitidine
8.6. Laxatives
8.6.1. Bulk Forming
8.6.1.1. Methylcellulose
8.6.1.2. Polycarbophil
8.6.1.3. Psyllium
8.6.2. Lubricant
8.6.3. Osmotic
8.6.3.1. Lactulose
8.6.3.2. Polyethylene Glycol
8.6.3.3. Sorbitol
8.6.4. Stimulant
8.6.5. Stool Softeners
8.7. Probiotics & Prebiotics
8.7.1. Prebiotics
8.7.1.1. Fructooligosaccharides
8.7.1.2. Inulin
8.7.2. Probiotics
8.7.2.1. Bifidobacterium
8.7.2.2. Lactobacillus
8.7.2.3. Saccharomyces Boulardii
8.8. Proton Pump Inhibitors
8.8.1. Esomeprazole
8.8.2. Lansoprazole
8.8.3. Omeprazole
8.8.4. Pantoprazole
8.8.5. Rabeprazole
9. Gastrointestinal Agents Market, by Route Of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.3.1. Bolus Injection
9.3.2. Infusion
9.4. Oral
9.4.1. Capsule
9.4.2. Liquid Syrup
9.4.3. Powder
9.4.4. Tablet
9.5. Topical
9.5.1. Creams
9.5.2. Gels
9.5.3. Suppositories
10. Gastrointestinal Agents Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Gastrointestinal Agents Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Gastrointestinal Agents Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Gastrointestinal Agents Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AbbVie Inc.
14.3.2. Takeda Pharmaceutical Company Limited
14.3.3. Pfizer Inc.
14.3.4. AstraZeneca PLC
14.3.5. Johnson & Johnson
14.3.6. Otsuka Pharmaceutical Co., Ltd.
14.3.7. Novartis AG
14.3.8. GlaxoSmithKline plc
14.3.9. Sanofi S.A.
14.3.10. Bayer AG
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. GASTROINTESTINAL AGENTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. GASTROINTESTINAL AGENTS MARKET: RESEARCHAI
FIGURE 22. GASTROINTESTINAL AGENTS MARKET: RESEARCHSTATISTICS
FIGURE 23. GASTROINTESTINAL AGENTS MARKET: RESEARCHCONTACTS
FIGURE 24. GASTROINTESTINAL AGENTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GASTROINTESTINAL AGENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 183. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 185. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 186. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 187. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 190. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 191. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 192. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 193. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 194. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 225. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2025-2030 (USD MILLION)
TABLE 227. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 232. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 233. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 234. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 235. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 236. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 237. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 240. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2025-2030 (USD MILLION)
TABLE 267. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 268. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 269. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 270. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 271. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2024 (USD MILLION)
TABLE 272. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2025-2030 (USD MILLION)
TABLE 273. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 278. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 279. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 280. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 281. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 282. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 283. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 286. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 287. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 288. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 289. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2024 (USD MILLION)
TABLE 290. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2025-2030 (USD MILLION)
TABLE 291. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2024 (USD MILLION)
TABLE 292. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2025-2030 (USD MILLION)
TABLE 293. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2024 (USD MILLION)
TABLE 294. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2025-2030 (USD MILLION)
TABLE 295. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2024 (USD MILLION)
TABLE 296. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2025-2030 (USD MILLION)
TABLE 297. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2024 (USD MILLION)
TABLE 298. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2025-2030 (USD MILLION)
TABLE 299. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 300. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 301. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 302. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 303. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 304. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 305. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 306. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 307. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 308. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 309. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2024 (USD MILLION)
TABLE 310. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2025-2030 (USD MILLION)
TABLE 311. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2024 (USD MILLION)
TABLE 312. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2025-2030 (USD MILLION)
TABLE 313. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 314. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 315. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
TABLE 316. CANADA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
TABLE 317. CANADA GASTROINTE

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Gastrointestinal Agents market report include:
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Novartis AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Bayer AG

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 63.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 80.51 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gastrointestinal Drugs Market by Drug Class (Antacids, Antidiarrheals, Antispasmodics), Route Of Administration (Injectable, Oral, Rectal), Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Gastrointestinal Drugs Market by Drug Class (Antacids, Antidiarrheals, Antispasmodics), Route Of Administration (Injectable, Oral, Rectal), Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Antacids Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Antacids Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Dyspepsia Drug Market by Drug Class (Antacids, H2-Receptor Antagonists, Prokinetics), Route Of Administration (Effervescent Granule, Oral Liquid, Oral Tablet), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Dyspepsia Drug Market by Drug Class (Antacids, H2-Receptor Antagonists, Prokinetics), Route Of Administration (Effervescent Granule, Oral Liquid, Oral Tablet), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Antacids Market Report by Drug Class, Formulation Type, Distribution Channel, and Region 2025-2033 - Product Image

Antacids Market Report by Drug Class, Formulation Type, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Antacids Market Report 2025 - Product Image

Antacids Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Gastrointestinal Agent Market

The Gastrointestinal Agent market is a subset of the Gastrointestinal Drugs market, which includes drugs used to treat diseases and disorders of the digestive system. These agents are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and antibiotics. Other agents, such as probiotics, are also used to treat gastrointestinal disorders. The Gastrointestinal Agent market is highly competitive, with many companies offering a variety of products. Major players in the market include Pfizer, GlaxoSmithKline, Merck, AstraZeneca, and Novartis. Other companies, such as AbbVie, Allergan, and Takeda, also offer products in this market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.